Status:
NOT_YET_RECRUITING
Relmacabtagene Autoleucel in Hematologic Malignancies
Lead Sponsor:
Shanghai Ming Ju Biotechnology Co., Ltd.
Conditions:
Lymphoma, B-Cell
Large B-cell Lymphoma
Eligibility:
All Genders
18+ years
Brief Summary
To evaluate the efficacy and safety of Relmacabtagene Autoleucel in the treatment of adult patients with hematologic malignancies in real-world
Detailed Description
The purpose of this study is to observationally evaluate the efficacy and safety data of Relmacabtagene Autoleucel for the treatment of patients with hematologic malignancies for up to 15 years after ...
Eligibility Criteria
Inclusion
- Signed informed consent
- Patients who have been treated with Relma-cel, including those who have received off-label products;
- If previously enrolled in another clinical study, they must have completed follow-up in the previous study, or have withdrawn or lost follow-up in the previous study.
Exclusion
- Patients who have been treated with Relma-cel and then have been treated with other CAR-T products.
Key Trial Info
Start Date :
December 28 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2038
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT06142188
Start Date
December 28 2023
End Date
December 31 2038
Last Update
November 21 2023
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Cancer Hospital
Beijing, Beijing Municipality, China, 100010
2
Peking University International Hospital
Beijing, Beijing Municipality, China, 100010